April 14th 2025
Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Fifty Percent of MS Patients Avoid Treatment Over Injectable Delivery Fears
November 19th 2009Around half of all multiple sclerosis (MS) patients that are eligible for treatment do not receive it and one in five of those patients that do begin therapy, delay doing so because of fear and anxiety over the treatment process, and not fear and anxiety about the disease.